Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Protein tyrosine phosphatases (PTPs) are an important class of enzymes that regulate protein tyrosine phosphorylation levels of a large variety of proteins in cells. Anomalies in protein tyrosine phosphorylation have been associated with the development of numerous human diseases, leading to a heigh...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2024-04, Vol.19 (7), p.e202300669-e202300669
Main Authors: Miao, Jinmin, Zhang, Zhong-Yin
Format: Article
Language:English
Subjects:
Affinity
Binding
Biodegradation
Chimeras
Drug development
Inhibitors
Phosphatase
Phosphorylation
Proteasomes
Proteins
Proteolysis
Therapeutic targets
Tyrosine
Ubiquitin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protein tyrosine phosphatases (PTPs) are an important class of enzymes that regulate protein tyrosine phosphorylation levels of a large variety of proteins in cells. Anomalies in protein tyrosine phosphorylation have been associated with the development of numerous human diseases, leading to a heightened interest in PTPs as promising targets for drug development. However, therapeutic targeting of PTPs has faced skepticism about their druggability. Besides the conventional small molecule inhibitors, proteolysis-targeting chimera (PROTAC) technology offers an alternative approach to target PTPs. PROTAC molecules utilize the ubiquitin-proteasome system to degrade specific proteins and have unique advantages compared with inhibitors: 1) PROTACs are highly efficient and can work at much lower concentrations than that expected based on their biophysical binding affinity; 2) PROTACs may achieve higher selectivity for the targeted protein than that dictated by their binding affinity alone; and 3) PROTACs may engage any region of the target protein in addition to the functional site. This review focuses on the latest advancement in the development of targeted PTP degraders and deliberates on the obstacles and prospective paths of harnessing this technology for therapeutic targeting of the PTPs.
ISSN:1860-7179
1860-7187
DOI:10.1002/cmdc.202300669